Ep 14 | All About 340B Grantees (Part 2)

340B Unscripted

This is part two of our two-part series focusing on 340B grantee-covered entities. The team talks about the importance of maintaining auditable records (15:34) and the challenges that many grantees face in meeting this 340B eligibility requirement. Also, they cover important billing considerations related to Medicaid Duplicate Discount prevention (31:20). Finally, the group debates future developments that 340B grantee-covered entities should keep on their radar through 2023 (45:52).

But first, Greg and Rob catch up on 340B implications from the Consolidated Appropriations Act of 2023 and share insights from a recent publication (J Manag Care Spec Pharm. 2023;29(3):229-35) that predicts which drugs will be subject to Medicare price negotiations starting in 2026 and beyond.